Inject PrEP to protect?
The first Pan European study exploring the willingness to use long acting injectable PrEP to prevent HIV.
The first Pan European study exploring the willingness to use long acting injectable PrEP to prevent HIV.
This online survey ran across Europe and sought to uncover who may benefit from the innovation that is long acting injectable PrEP. The European Commission (EC) has authorised Apretude (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention. The availability of cabotegravir LA for PrEP will differ from country to country across the EU. It is important for health services and policy makers to understand who may be interested in taking long acting injectable PrEP so that resources can be most effectively allocated. The PROTECT survey was for people from the following groups:
The survey took participants about 20 minutes to complete, depending on their characteristics. It was anonymous and participants could withdraw at anytime. It was important to hear from a wide variety of people across Europe about their experiences and preferences. HIV can affect anyone and the nature of the epidemic has been changing in recent years. Men who have sex with men continue to be a group that is heavily impacted by the virus but so are people with a transgender experience and increasingly also heterosexual people.
The PROTECT team is presenting analysis of PROTECT survey data at the 25th International AIDS Conference in Munich. The following in person poster presentations will be given:
Our multidisciplinary team comes from around the world and works from Maastricht, a cross-roads between the Netherlands, Germany and Belgium. We have experience with creating and analysing similar large online surveys such as EMIS (The European Men who have sex with Men Internet Survey) and have expertise in HIV prevention and Lesbian, Gay, Bisexual, Transgender, Intersex, Queer (LGBTIQ) health.